Concept Life Sciences Expands Integrated Drug Development Services Through FEI Registration and Investment in Additional ICH Stability Capacity
https://www.businesswire.com/news/home/20180716005238/en/
MANCHESTER, England--(BUSINESS WIRE)--Jul 16, 2018--Concept Life Sciences (“Concept”), the integrated drug discovery, development and analytical services company, today announced it has achieved FEI (FDA Establishment Identifier ) registration and commissioned a 10-fold expansion of its ICH stability storage facilities, to enhance the Company’s integrated drug development services offering.
The FEI registration and additional storage capacity allows Concept to release pharmaceutical raw materials and finished products for the US market, as a named test facility, and to support Investigational New Drug (IND) and Abbreviated New Drug (ANDA) applications for new and generic drugs in development. The registration also enables Concept to provide a consistent continuum of analytical support from early method development to commercial launch.